Eliem Therapeutics to change corporate name to Climb Bio

Eliem Therapeutics announced that it will change its corporate name to Climb Bio. The new name and corporate brand reflect the Company’s new mission to develop a pipeline focused on immune-mediated diseases, following its acquisition of Tenet Medicines, Inc. In conjunction with the corporate name change, the Company will begin trading under the new ticker symbol “CLYM” on the Nasdaq Global Market at the open of the market on October 3. Budoprutug, formerly TNT119, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. In a Phase 1b clinical trial of budoprutug in membranous nephropathy, 3 out of 5 of patients that received four doses of budoprutug achieved a complete remission of proteinuria, a primary symptom of membranous nephropathy.